Puneeth Iyengar on the Benefits of Hypofractionated Radiation Therapy in Lung Cancer

Name: Puneeth Iyengar on the Benefits of Hypofractionated Radiation Therapy in Lung Cancer
Uploaded: 2016-10-26T19:28:53.000Z
Description: Dr. Puneeth Iyengar discusses the use of a hypofractioned course of radiation therapy for patients with stage 3 NSCLC instead of a combination of chemotherapy and radiation.

October 26, 2016

Puneeth Iyengar, MD, PhD

Video

Dr. Puneeth Iyengar discusses the use of a hypofractioned course of radiation therapy for patients with stage 3 NSCLC instead of a combination of chemotherapy and radiation.

Puneeth Iyengar, MD, PhD, assistant professor of Radiation Oncology at UT Southwestern Medical Center, discusses the use of a hypofractionated course of radiation therapy for patients with stage 3 NSCLC.

The current standard therapy for stage 3 NSCLC is a combination of chemotherapy and radiation. Some patients are unable to tolerate chemotherapy for a variety of reasons and receive 6 weeks of radiation therapy instead. Iyengar's study compared that conventional schedule with a hypofractionated course, for just 3 weeks.

Related Content

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

April 18th 2024

Article

Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023

Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024

Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Adagrasib Provides Greater Benefit vs Docetaxel in KRAS G12C–Mutant NSCLC

April 9th 2024

Article

Compared with docetaxel, adagrasib improved progression-free survival and objective response rate in patients with pretreated KRAS G12C–mutant non–small cell lung cancer.

TTFields Improves Time to Progression in Brain Metastases From NSCLC

April 8th 2024

Article

Tumor-treating fields significantly improved the time to intracranial progression in patients from the phase 3 METIS trial with brain metastases from non-small cell lung cancer.

Related Content

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

April 18th 2024

Article

Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023

Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024

Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

A Look Back at 2022 FDA Approvals in Oncology

January 2nd 2023

Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Adagrasib Provides Greater Benefit vs Docetaxel in KRAS G12C–Mutant NSCLC

April 9th 2024

Article

Compared with docetaxel, adagrasib improved progression-free survival and objective response rate in patients with pretreated KRAS G12C–mutant non–small cell lung cancer.

TTFields Improves Time to Progression in Brain Metastases From NSCLC

April 8th 2024

Article

Tumor-treating fields significantly improved the time to intracranial progression in patients from the phase 3 METIS trial with brain metastases from non-small cell lung cancer.